Inhibrx Biosciences (INBX) Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Non-Current Assets data on file, last reported at $13.6 million in Q4 2025.

• On a quarterly basis, Non-Current Assets fell 33.01% year-over-year to $13.6 million in Q4 2025; TTM through Dec 2025 was $67.1 million, a 4.22% increase from a year earlier, with the FY2025 full-year figure at $13.6 million, down 33.01% from the prior year.
• Non-Current Assets for Q4 2025 stood at $13.6 million, down from $16.0 million in the prior quarter.
• Over the last five years, Non-Current Assets for INBX reached as high as $20.4 million in Q4 2024 and fell as low as $12.5 million in Q4 2023.
• Historically, Non-Current Assets has averaged $16.4 million across 3 years, with a median of $16.2 million in 2024.
• Across the five-year window, Non-Current Assets surged 62.5% in 2024 and sank 33.01% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $12.5 million in 2023, then soared by 62.5% to $20.4 million in 2024, then sank by 33.01% to $13.6 million in 2025.
• Per Business Quant data, the three most recent Non-Current Assets figures were $13.6 million in Q4 2025, $16.0 million in Q3 2025, and $18.2 million in Q2 2025.